X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1530) 1530
Book Review (134) 134
Publication (42) 42
Newsletter (11) 11
Magazine Article (7) 7
Book Chapter (1) 1
Conference Proceeding (1) 1
Newspaper Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1314) 1314
humans (880) 880
male (629) 629
animals (527) 527
sorbitol (515) 515
sorbitol - therapeutic use (453) 453
female (413) 413
rats (316) 316
adult (305) 305
pharmacology & pharmacy (285) 285
middle aged (267) 267
sorbitol - metabolism (218) 218
aged (163) 163
aldehyde reductase - antagonists & inhibitors (160) 160
sorbitol - analogs & derivatives (150) 150
sorbitol - pharmacology (149) 149
sorbitol - administration & dosage (140) 140
abridged index medicus (131) 131
time factors (115) 115
aldose reductase (114) 114
mice (109) 109
diabetes (108) 108
dentistry (104) 104
sorbitol - chemistry (98) 98
glucose (97) 97
drug combinations (94) 94
adolescent (91) 91
child (90) 90
endocrinology & metabolism (84) 84
oxidative stress (82) 82
analysis (78) 78
double-blind method (78) 78
xylitol (76) 76
xylitol - therapeutic use (75) 75
blood glucose - metabolism (74) 74
complications (71) 71
diabetes mellitus, experimental - drug therapy (71) 71
dentistry, oral surgery & medicine (68) 68
rats, sprague-dawley (68) 68
diabetic neuropathies - drug therapy (67) 67
rats, inbred strains (65) 65
clinical trials as topic (64) 64
toxicology (62) 62
dental caries - prevention & control (61) 61
biochemistry & molecular biology (60) 60
proteins (58) 58
rats, wistar (58) 58
chewing gum (57) 57
imidazolidines (57) 57
physiological aspects (56) 56
polyol pathway (56) 56
research (56) 56
sorbitol - adverse effects (56) 56
diabetes mellitus, experimental - metabolism (55) 55
health aspects (55) 55
diabetes mellitus (54) 54
treatment outcome (54) 54
aldehyde reductase - metabolism (53) 53
chemistry, medicinal (53) 53
child, preschool (53) 53
diabetes mellitus, experimental - physiopathology (53) 53
glucose - metabolism (53) 53
prevention (53) 53
sorbitol - blood (53) 53
dose-response relationship, drug (52) 52
kinetics (51) 51
dextrose (50) 50
fructose (50) 50
metabolism (49) 49
administration, oral (48) 48
infant (48) 48
medicine, general & internal (48) 48
chemistry, multidisciplinary (47) 47
fructose - metabolism (47) 47
imidazoles - therapeutic use (47) 47
hypoglycemic agents - therapeutic use (46) 46
in-vitro (46) 46
diabetes mellitus, type 2 - drug therapy (45) 45
disease models, animal (45) 45
inositol - metabolism (45) 45
sugars (45) 45
diabetic neuropathies - physiopathology (44) 44
hydrogen-ion concentration (44) 44
mannitol - therapeutic use (44) 44
neuropathy (43) 43
polyols (43) 43
cariostatic agents - therapeutic use (42) 42
neural conduction - drug effects (41) 41
sucrose (41) 41
enzyme inhibitors - pharmacology (40) 40
mannitol (40) 40
sorbitol - analysis (40) 40
osmolar concentration (39) 39
sweetening agents - therapeutic use (39) 39
aldose reductase inhibitor (38) 38
enzyme inhibitors - therapeutic use (38) 38
iron - therapeutic use (38) 38
medicine, research & experimental (38) 38
pharmacology/toxicology (38) 38
stability (38) 38
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1270) 1270
German (112) 112
Russian (49) 49
French (45) 45
Italian (15) 15
Spanish (12) 12
Japanese (11) 11
Chinese (8) 8
Portuguese (4) 4
Romanian (4) 4
Bulgarian (3) 3
Czech (3) 3
Polish (3) 3
Ukrainian (3) 3
Serbian (2) 2
Slovak (2) 2
Danish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2018, Volume 20, Issue 2, pp. 438 - 442
This study aimed to assess the effect of luseogliflozin on liver fat deposition and compare luseogliflozin to metformin in type 2 diabetes (T2D) patients with... 
antidiabetic drug | SGLT2 inhibitor | fatty liver | GLUCAGON-SECRETION | TRIAL | EFFICACY | SAFETY | SGLT2 INHIBITOR LUSEOGLIFLOZIN | ENDOCRINOLOGY & METABOLISM | STEATOHEPATITIS | MELLITUS | JAPANESE PATIENTS | Glycated Hemoglobin A - analysis | Liver - pathology | Metformin - therapeutic use | Humans | Middle Aged | Male | Tomography, X-Ray Computed | Diabetes Mellitus, Type 2 - metabolism | Weight Loss - drug effects | Metformin - adverse effects | Non-alcoholic Fatty Liver Disease - complications | Drug Therapy, Combination - adverse effects | Liver - drug effects | Sorbitol - analogs & derivatives | Liver - diagnostic imaging | Ultrasonography | Female | Diabetes Mellitus, Type 2 - complications | Hypoglycemic Agents - therapeutic use | Non-alcoholic Fatty Liver Disease - diagnostic imaging | Adiposity - drug effects | Sodium-Glucose Transporter 2 - metabolism | Liver - metabolism | Non-alcoholic Fatty Liver Disease - metabolism | Non-alcoholic Fatty Liver Disease - drug therapy | Lipotropic Agents - therapeutic use | Diabetes Mellitus, Type 2 - blood | Organ Size - drug effects | Pilot Projects | Lipid Metabolism - drug effects | Membrane Transport Modulators - therapeutic use | Sorbitol - adverse effects | Diabetes Mellitus, Type 2 - drug therapy | Membrane Transport Modulators - adverse effects | Hypoglycemic Agents - adverse effects | Sorbitol - therapeutic use | Type 2 diabetes | Fatty liver | Glycosylated hemoglobin | Hypoglycemic agents | Diagnostic imaging | Comparative analysis | Diabetes therapy | Spleen | Alanine | Liver diseases | Fasting | Diabetes mellitus | Glucose | Body mass index | Computed tomography | Hemoglobin | Alanine transaminase | Diabetes | Metformin | Immunoreactivity | Diabetes mellitus (non-insulin dependent) | Index Medicus
Journal Article
Journal of Hypertension, ISSN 0263-6352, 05/2016, Volume 34, Issue 5, pp. 893 - 906
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 05/2017, Volume 19, Issue 5, pp. 739 - 743
This study investigated the safety and efficacy of the sodium‐glucose co‐transporter‐2 ( SGLT2 ) inhibitor luseogliflozin with differing carbohydrate intakes... 
type 2 diabetes | inhibitor | glucose variability | SGLT2 | carbohydrate intake | luseogliflozin | continuous glucose monitoring | glycaemic index | SGLT2 inhibitor | COTRANSPORTER 2 INHIBITORS | DAPAGLIFLOZIN | MECHANISM | SGLT2 INHIBITORS | SAFETY | KETOACIDOSIS | MELLITUS | BLIND | ENDOCRINOLOGY & METABOLISM | Glycated Hemoglobin A - analysis | Humans | Middle Aged | Diabetic Ketoacidosis - etiology | Diabetes Mellitus, Type 2 - diet therapy | Male | Diabetes Mellitus, Type 2 - metabolism | Dietary Carbohydrates - metabolism | Hypoglycemia - prevention & control | Monitoring, Physiologic | Sorbitol - analogs & derivatives | Diet, Carbohydrate-Restricted - adverse effects | Diabetic Ketoacidosis - prevention & control | Female | Dietary Carbohydrates - administration & dosage | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Blood Glucose - analysis | Glycemic Index | Sodium-Glucose Transporter 2 - metabolism | Japan | Combined Modality Therapy | Diet, Diabetic - methods | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Diabetes Mellitus, Type 2 - blood | Ketone Bodies - blood | Membrane Transport Modulators - therapeutic use | Sorbitol - adverse effects | Diabetes Mellitus, Type 2 - drug therapy | Membrane Transport Modulators - adverse effects | Hypoglycemic Agents - adverse effects | Sorbitol - therapeutic use | Carbohydrates | Glucose | Diabetes | Index Medicus | Brief Reports | Brief Report
Journal Article
Internal Medicine, ISSN 0918-2918, 2017, Volume 56, Issue 6, pp. 597 - 604
Objective and Methods An SGLT2 inhibitor (ipragliflozin, dapagliflozin, luseogliflozin, tofogliflozin, or canagliflozin) was administered to 132 outpatients... 
renal function | glycemic control | SGLT2 inhibitor | visceral fat | oral hypoglycemic agent | Glycemic control | Visceral fat | Renal function | Oral hypoglycemic agent | METFORMIN | EFFICACY | DAPAGLIFLOZIN | SAFETY | MELLITUS | IPRAGLIFLOZIN | INADEQUATE GLYCEMIC CONTROL | MEDICINE, GENERAL & INTERNAL | DOUBLE-BLIND | JAPANESE PATIENTS | EMPAGLIFLOZIN MONOTHERAPY | Thiophenes - therapeutic use | Intra-Abdominal Fat - physiopathology | Body Weight | Canagliflozin - pharmacology | Humans | Middle Aged | Male | Kidney Function Tests | Glomerular Filtration Rate - drug effects | Sorbitol - analogs & derivatives | Body Composition - drug effects | Canagliflozin - therapeutic use | Glycated Hemoglobin A | Aged, 80 and over | Adult | Female | Glucosides - therapeutic use | Blood Pressure - drug effects | Intra-Abdominal Fat - drug effects | Benzhydryl Compounds - therapeutic use | Hypoglycemic Agents - therapeutic use | Glucosides - pharmacology | Thiophenes - pharmacology | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Hypoglycemic Agents - pharmacology | Diabetes Mellitus, Type 2 - blood | Aged | Benzhydryl Compounds - pharmacology | Diabetes Mellitus, Type 2 - drug therapy | Sorbitol - pharmacology | Sorbitol - therapeutic use | g-Glutamyltransferase | Body weight | Pruritus | Glucose | Ingestion | Hunger | Hemoglobin | Blood pressure | Pretreatment | Diabetes mellitus (non-insulin dependent) | Cystitis | Glucose transporter | Creatinine | Alanine | Level (quantity) | Epidermal growth factor receptors | Diabetes mellitus | Nausea | Uric acid | Hypoglycemia | Inhibitors | Sodium | Alanine transaminase | Diabetes | Health risk assessment | Transporter | Index Medicus | Original
Journal Article
Journal Article
Journal Article